Physician profile
Larry Wayne Freeman
NPI 1275511396
$945.32
in general payments reported to CMS, 2019-2025
12 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2022: $125 · 2023: $47.03 · 2024: $52.88 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $505.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $154.27 | 2022-2024 | Tyrvaya |
| Alcon Vision LLC | $151.94 | 2025 | Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $117.38 | 2019-2025 | |
| Glaukos Corporation | $107.05 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.99 | 2019 | |
| Bausch & Lomb Americas INC. | $71.23 | 2025 | Miebo |
| Thea Pharma INC. | $68.80 | 2023-2025 | Iyuzeh |
| Abbvie INC. | $68.06 | 2025 | |
| Ocular Therapeutix, INC. | $46.00 | 2019 | |
| Allergan, INC. | $21.44 | 2019 | |
| Amgen INC. | $20.78 | 2025 | Tepezza |
| Shire North American Group INC | $18.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.